Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 474121 Single Rising Doses in Healthy Japanese Males
NCT04964453Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BI 474121 in Alzheimer's disease (AD) and schizophrenia (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Subjects With Drug-related Adverse Events at 8 days. Started Jul 2021; status: completed.
02
Drugs
BI 474121
03
Conditions
Alzheimer's disease (AD)schizophrenia
Beyond the preview
Go deeper on NCT04964453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04964453.